Data collection
Epidemiological, clinical and laboratory data of all patients with
laboratory-confirmed SARS-CoV-2 were obtained with data collection forms
from the electronic medical records of each patient. The data collected
included demographics, comorbidities, the use of any potentially
hepatotoxic medications, and lab results available from a primary health
care setting within the range of one year prior to admission. Upon their
admission, the severity of all patients was recorded and their labs
results and outcomes during hospitalization were extracted from the
electronic medical file.
Patients with known hepatic pathology or autoimmune phenotypes (such as
alcoholic liver disease, drug-induced liver injury, autoimmune
hepatitis, viral hepatitis, cholestatic liver disease and
metabolic/genetic liver disease) were excluded using specific clinical,
laboratory, radiological and/or histological criteria/tests (serology of
viral hepatitis A, B, and C, autoimmune markers including ANA, anti-LKM,
anti-smooth mussels protein electrophoresis, immune electrophoresis,
metabolic markers such as serum ceruloplasmin, 24-h urine collection for
copper, ferritin, iron, transferrin saturation, TSH, HbA1c and alpha-1
antitrypsin).